THURSDAY, Feb. 6, 2025 (HealthDay News) -- A few baseline characteristics can predict the need for recurrent endoscopic sinus ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

Oxidative stress plays a critical role in the pathogenesis of upper and lower respiratory tract diseases, such as chronic rhinosinusitis with nasal polyps (CRSwNP), allergic rhinitis (AR), and asthma ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...

WILMINGTON, Del., November 08, 2024--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that ...

UPDATED: Friday, Jan. 3 at 2:45 p.m. ET GSK’s IL-5 inhibitor Nucala scored a nod in China to treat people with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a ...

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...